AbbVie JUVMO (Tavapadon) Wins FDA Approval as First Selective D1/D5 Receptor Agonist for Parkinson’s Disease
AbbVie JUVMO (tavapadon) has received FDA approval as the first selective D1/D5 receptor agonist for adults with Parkinson’s disease. AbbVie expects U.S. availability in October 2026.
